Page last updated: 2024-11-11

mofarotene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mofarotene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5467732
CHEMBL ID146506
SCHEMBL ID62905
MeSH IDM0216513

Synonyms (19)

Synonym
mofarotene
mofarotene [inn]
4-(2-(p-((e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl)phenoxy)ethyl)morpholine
4-[2-[p-[(e)-2-(5,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]phenoxy]ethyl]morpholine
nsc658402
nsc-658402
4-(2-{4-[(1e)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl]phenoxy}ethyl)morpholine
125533-88-2
ro 40-8757
ro-408757
CHEMBL146506
4-[2-[4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine
unii-8k3cvy8f8v
8k3cvy8f8v ,
mofarotene [mi]
4-(2-(4-((e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl)phenyloxy)ethyl)morpholine
SCHEMBL62905
DTXSID7032006
Q27270660

Research Excerpts

Actions

ExcerptReferenceRelevance
"Mofarotene did not inhibit colony formation by bone marrow cells stimulated by exogenous growth factors and did not decrease production of growth factors by stromal cells in the cultures, as determined by functional assays and by mRNA levels."( Mofarotene (Ro 40-8757) inhibits hematopoiesis in vitro by preventing maturation from primitive progenitor cells.
Baumgartner, M; Eliason, JF; Hirabayashi, Y; Inoue, T; Mitsui, H; Yoshikubo, T, 1995
)
2.46

Toxicity

ExcerptReferenceRelevance
" Treatment of mice with the combination demonstrated that the marrow progenitors were protected from the toxic effects of CPA by the arotinoid."( The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of cyclophosphamide.
Eliason, JF; Hartmann, D; Horii, I; Inoue, T; Kubota, A; Teelmann, K, 1993
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The data indicate a similar disposition for mofarotene in all species studied: low clearance consistent with a high bioavailability following oral dosing, and large volume of distribution indicating an extensive tissue uptake."( In vivo and in vitro kinetics of mofarotene in mouse, rat, dog and man.
Ba, B; Coassolo, P; Reigner, B; Vallès, B; Wyss, R,
)
0.67

Dosage Studied

ExcerptRelevanceReference
" This fell outside the range subsequently obtained in healthy volunteers dosed orally with 300 mg of mofarotene (7."( A new extrapolation method from animals to man: application to a metabolized compound, mofarotene.
Ba, B; Brandt, R; Chou, RC; Coassolo, P; Lave, T; Schmitt-Hoffmann, AH; Ubeaud, G; Valles, B, 1995
)
0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID21849In vitro clearance in dog in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21857In vivo clearance in human.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21854In vivo clearance in dog.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21859In vivo clearance in rat.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's20 (83.33)18.2507
2000's4 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.00%)5.53%
Reviews1 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (84.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]